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AbstrACt
Introduction Low back pain (LBP) is the most prevalent 
musculoskeletal condition in the UK. Guidelines advocate 
a multimodal approach, including prescription of 
medications. Advanced physiotherapy practitioners (APPs) 
are well placed to provide this care in primary care. 
Physiotherapist independent prescribing remains novel, 
with the first prescribers qualifying in 2014. This feasibility 
trial aims to evaluate the feasibility, suitability and 
acceptability of assessing the effectiveness of independent 
prescribing by APPs for patients with LBP in primary care, 
to inform the design of a future definitive stepped-wedged 
cluster trial.
Method and analysis (1) Trial component. An APP 
(registered prescriber) will complete the initial participant 
consultation. If prescription drugs are required within 
the multimodal physiotherapeutic context, these will 
be prescribed. Patient-reported outcome measures will 
be completed prior to initial assessment and at 6 and 
12 weeks to assess feasibility of follow-up and data 
collection procedures. Accelerometers will be fitted for 7 
days to assess physical activity, sedentary behaviour and 
feasibility of use. (2) Embedded qualitative component. A 
focus group and semistructured interviews will be used 
to evaluate the views and experiences of the participants 
and APPs respectively, about the feasibility, suitability 
and acceptability of the proposed full trial. A Consolidated 
Standards of Reporting Trials diagram will be used to 
analyse feasible eligibility, recruitment and follow-up 
rates. Descriptive analysis of the data will be completed 
to evaluate procedures. Thematic analysis will be used to 
analyse and synthesise the qualitative data.
Ethics and dissemination This feasibility trial is 
approved by the Health Research Authority (HRA). Ethical 
approval was sought and granted via the Integrated 
Research Application System (IRAS) ID 250734. Data 
will be disseminated via publication in peer reviewed 
journal and conference presentation. It is anticipated 
that the results of this study will be used in conjunction 
with ethical evaluation, economic and risk analyses, as 
well as consultation with key stakeholders including the 
British health consumer when contemplating change, 
enhancement or redesign of the essential full randomised 
controlled trial.
trial registration number ISRCTN15516596, Pre-results.
bACkground
Low back pain (LBP) is the most prevalent 
musculoskeletal condition in the UK, with 
58%–84% of the population experiencing 
LBP in their lifetime.1–3 At any time, 28.5% of 
adults >25 years are experiencing LBP.2 Data 
indicate that 3.2 million work days are lost per 
year in the UK, with an average of 16.5 days 
lost per case.4 Approximately 20% of those 
with LBP seek care from their general practi-
tioner (GP),1 with 7% of all GP consultations 
being due to LBP.3 5 
Despite increased funding for treat-
ments and a growing understanding of the 
complex biopsychosocial nature of LBP 
leading to improvements in assessment and 
management of the condition, up to 7% 
of the general population in the UK have 
chronic LBP associated with significant 
disability1 2 and the health and function of 
this demographic continues to decline.6 In 
an attempt to address this, novel approaches 
have been adopted to inform shared deci-
sion-making, and stratification tools are being 
used to improve outcomes through recog-
nising clinical heterogeneity, ensuring that 
strengths and limitations of this study
 ► First rigorous investigation aiming to evaluate the 
methods required to assess the clinical and cost-ef-
fectiveness of independent prescribing by advanced 
physiotherapists for patients with low back pain in 
primary care.
 ► The design of this feasibility trial was developed 
by clinicians, academics, methodological experts, 
healthcare service managers, professional leaders 
and the public/patients.
 ► The methods will be tested across a range of cities, 
towns and villages in varying geographical areas 
across England.
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all biopsychosocial risk factors are addressed, improving 
patient management and reducing the overall cost of 
healthcare.6–8 Early assessment, diagnosis and treatment 
of LBP has been seen to reduce chronicity.1 However, the 
complex and multidimensional nature of LBP combined 
with a current deficit in the availability of GPs in the UK9 10 
has prompted the redesign of outdated traditional LBP 
clinical pathways, and the introduction of new treatment 
models designed to maximise clinical and cost-effective-
ness, while readying the health services for the future.10–12
Physiotherapists are experts in the assessment, diagnosis 
and treatment of musculoskeletal disorders.13 For >30 
years, physiotherapists have been working in advanced 
practice roles across the country, using their scope of 
practice to optimise patient care, providing support in 
health services where the availability of medical practi-
tioners does not meet the demands of a local commu-
nity.13 14 Advanced musculoskeletal physiotherapists 
have been shown to be clinically and cost-effective when 
working in a variety of settings including orthopaedic 
and emergency care departments as well as in primary 
care in musculoskeletal interface services.14–16 Recently, 
the success and experience of these practitioners, along-
side changes in demographics and predictions that GP 
numbers will further reduce by 2020, have prompted 
successful pilot studies investigating the effectiveness 
of first contact advanced physiotherapy practitioners 
(FCPs) in primary care.11 17 As a result, Health Education 
England, in collaboration with NHS England, the Royal 
College of General Practitioners (RCGP), the British 
Medical Association and the Chartered Society of Physio-
therapy have committed to introducing these roles across 
England.17–19
Recently published guidelines from the National Insti-
tute for Health and Care Excellence (NICE)8 for LBP and 
sciatica, advocate for a holistic, multimodal approach to 
assessment and management.3 Advanced physiothera-
pists are well placed to provide this care owing to their 
competency in physical therapies including manual and 
exercise therapy; knowledge and skills associated with the 
management of psychosocial factors and ability to appro-
priately refer for blood tests, imaging, spinal injections, 
denervation and surgery.20 21 Further, the NICE guide-
lines recommend the use of drugs that are helpful and 
minimise harm.3 8 It is therefore envisaged that indepen-
dent physiotherapist prescribing will be a key competency 
required for the successful implementation of first contact 
advanced physiotherapists working in primary care.
Independent physiotherapist prescribing remains rela-
tively new, with the first prescribers qualifying in 2014. 
Evaluation of physiotherapist and podiatrist independent 
prescribing has shown good acceptance by patients and 
a good safety record to date.22 A recent mixed-methods 
systematic review of investigating the barriers and facili-
tators of non-medical prescribing (NMP) concludes that 
the successful implementation and utilisation of NMP is 
dependent on adequate preparation and organisation 
of a range of factors.23 Considerations such as the use of 
advanced physiotherapists in primary care were seen to 
facilitate successful implementation of NMP as long as 
clinical governance, policy development and service prac-
ticalities and logistics are adequately developed and estab-
lished prior to implementing NMP. To ensure longevity 
and future growth, education, support and financial 
factors alongside the management of personal and profes-
sional considerations were also deemed paramount.23
For clinical services to be successful, they must deliver 
positive clinical outcomes in a safe and economically 
sound manner.24 Our recent rigorous systematic review 
investigating the clinical and cost-effectiveness of NMP 
across all professions and clinical settings, identified 
limited evidence with unclear risk of bias.25 We concluded 
that quantifiable benefits of NMP remain unknown and 
called for adequately powered, low risk of bias randomised 
controlled trials (RCTs) in specific patient groups, profes-
sions and clinical settings.25 Owing to the contemporary 
nature of independent physiotherapist prescribing, no 
trial has examined the clinical or cost-effectiveness of this 
intervention in the complex context of LBP. Trial design 
required careful consideration, particularly, as indepen-
dent physiotherapy prescribing is within the process of 
implementation across private health services and NHS 
Trusts. A feasibility study is therefore required to inform 
a multicentre RCT investigating physiotherapist inde-
pendent prescribing by advanced physiotherapists for 
patients with LBP, in primary care. The project will aim 
to evaluate the feasibility, suitability and acceptability of 
procedures and outcomes for use in the full trial, also 
assessing the commitment and burden on participants, 
clinicians and researchers as well as infrastructure and 
technological requirements.
AIM
To evaluate the feasibility, suitability and acceptability of 
assessing the effectiveness of independent prescribing by 
advanced physiotherapy practitioners (APPs) for patients 
with LBP in primary care to inform the design of a future 
definitive stepped-wedged cluster trial.
objECtIvEs
general objectives
 ► To assess the feasibility, suitability and acceptability of 
the proposed full trial26 including the following:
 – Eligibility criteria.27–29
 – Recruitment strategy.27–29
 – Data collection methods.27–29
 – Follow-up procedures.27 28
specific objectives
Feasibility
 ► To evaluate participant recruitment rates.26–28
 ► To evaluate the ease of fitting participants with accel-
erometers and ease of data collection.27 28
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 ► To evaluate the capacity (time and effort) of clinicians 
and researchers to complete trial-related tasks.27 28
 ► To evaluate the necessary training required by clini-
cians to successfully implement a full trial.27 28
Suitability
 ► To evaluate the range of participants’ scores on the 
Roland and Morris Disability Questionnaire (RMDQ), 
assessing for floor effects and therefore the appropri-
ateness of outcome measure for use in a full trial.26–29
 ► To evaluate participant compliance with wearing the 
accelerometer device.27 28
 ► To evaluate the time required to conduct each stage 
of the protocol.27 28
 ► To evaluate the appropriateness and availability of 
services and infrastructure such as access to national 
and institutional communication and information 
technologies required to undertake a full trial.27 28
Acceptability
 ► To evaluate the acceptability of the intervention to 
patients and the public.26–29
MEthods
To ensure transparency and reproducibility, this feasi-
bility trial protocol has been registered on the ISRCTN 
database and is reported in line with the CONSORT 2010 
statement: extension to randomised pilot and feasibility 
trials,30–32 with all patient and public involvement (PPI) 
reported in line with the GRIPP2 short form reporting 
checklist.33 34
The feasibility trial will use a mixed-methods research 
approach, comprising the following:
 ► A quantitative one-armed feasibility trial.
 ► Qualitative semistructured interviews and patient 
focus groups, using thematic analysis.
Mixed-methods designs are recognised to enable a 
richer synthesis, generating data that will facilitate appro-
priate change.35–37
design
RCTs are considered the gold standard for evaluating the 
effectiveness of an intervention.38 Cluster RCTs (cRCTs) 
allowing for randomisation by group have been devel-
oped to overcome practical issues in clinical settings, 
where individual randomisation is not convenient or 
feasible.38–40 When evaluating contemporary interven-
tions, parallel deigns requiring the new intervention to 
be simultaneously provided to multiple clusters of partic-
ipants are often too costly or not practical owing to the 
necessary clinician training required to deliver the inter-
vention safely.38 39 A stepped-wedge cluster randomised 
controlled trial (SWcRCT) design will therefore be used 
to evaluate the clinical and cost-effectiveness of physio-
therapist prescribing for LBP in the future. This design is 
valuable when evaluating innovative clinical interventions 
where there is a strong ethical belief that the intervention 
will benefit patients.39 41 42 SWcRCTs allow each experi-
mental cluster to begin in the control arm then cross 
over to the experimental arm at specified time points 
(figure 1).41 As the implementation of independent phys-
iotherapy prescribing and the utilisation of APPs working 
as FCPs are both relatively contemporary innovations, 
there are limited numbers of clinicians currently working 
in these innovative roles who are registered to prescribe. 
This research design allows for the use of fewer clinicians 
than those required for a parallel design and is therefore 
more reflective of current practice. APPs who are not 
prescribers will start in the control group and cross to the 
experimental group following registration as an indepen-
dent prescriber. APPs who are not prescribers start in the 
control group and cross to the experimental group.39–42
Figure 1 The SWcRCT design for potential use in a full trial. APP, advanced physiotherapy practitioner; FCP, first contact 
advanced physiotherapy practitioner; SWcRCT, stepped-wedge cluster randomised controlled trial.
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Currently, no clear framework exists describing the 
requirements for best practice when completing feasi-
bility trials in preparation for SWcRCTs.43 Two-arm 
feasibility trials that have aimed to calculate intracluster 
correlation coefficients required for sample size calcu-
lations in preparation for full cRCTs have demonstrated 
insufficient accuracy, unless the feasibility trial is equal in 
size to the proposed full trial.43 Therefore, a single-arm 
feasibility design will be employed to test specific aspects 
of the trial protocol in terms of feasibility, suitability 
and acceptability on the experimental arm of the future 
SWcRCT, without sample size estimation.27 44 45
trial component
A prospective, mixed-methods, single-group feasibility 
trial will be used to evaluate the trial objectives.29 44 Partic-
ipant consent forms (online supplementary file 1) and 
patient-reported outcome measures (online supple-
mentary file 2) will be completed digitally via an online 
survey at initial assessment (baseline) and at 6 and 12 
weeks (12 weeks is the planned primary end point of the 
definitive trial) following a prescription being issued, 
to evaluate the feasibility of follow-up data collection 
procedure.45 46 Follow-up time points have been selected 
in line with the prognostic literature showing that 40% 
of patients presenting to primary care with LBP will be 
pain-free 6 weeks post onset, with 58% pain-free by 12 
weeks.47–49 The online outcome measures survey will be 
built using REDCap (Research Electronic Data Capture) 
software (hosted in the Centre for Precision Rehabili-
tation for Spinal Pain [CPR Spine] at the University of 
Birmingham, UK), enabling data to be captured and 
stored in real time, on a range of electronic devices.50 
Baseline measurements will be completed by the partic-
ipants within the clinical setting. A link to the online 
outcome measures survey with instructions will be emailed 
to participants for completion at 6 and 12 weeks. If partic-
ipants forget to complete the outcome questionnaire on 
the required day, a reminder to complete it will be sent 
at 24 and 48 hours after the deadline to facilitate compli-
ance.45 51 To evaluate the feasibility of fitting participants 
with accelerometers in clinic, the ease of data collection 
and participant compliance with wearing the accelerom-
eter device,27 28 n=10 participants at one research site will 
be fitted with an accelerometer to wear for 7 days immedi-
ately following completion of patient-reported outcome 
measures at the first consultation. Participants will be 
provided with stamped/addressed envelopes in which to 
return the devices after use.
Participants
Potential participants will be identified by the APPs 
at each clinical site, by using the STarT Back Tool at 
initial assessment, to stratify all patients presenting with 
LBP.7 Patients stratified into the medium risk group by 
the STarT Back Tool will be eligible for recruitment if 
they meet the inclusion criteria following assessment 
(box 1). This group of patients have been recognised 
as predominant cohort presenting for assessment and 
treatment of LBP in primary care; exhibiting both phys-
ical and psychosocial prognostic factors and may require 
physiotherapist prescribing to optimise their multimodal 
physiotherapeutic treatment.7 52–54 Convenience sampling 
will be adopted, as this method has the advantages of 
fluid recruitment and follow-up required by feasibility 
trials, with good retention of participants where time 
is limited.28 45 46 55 Patients who are interested in partic-
ipating will be provided with a participant information 
sheet (online supplementary file 3) explaining the ratio-
nale, content and research dissemination plans to ensure 
ethical recruitment of participants. The physiothera-
pist will answer any questions and if the patient wishes 
to participate, consent will be obtained using an online 
consent form. Contact details for the research team will 
be provided to give the participants the opportunity to 
have any further questions answered. Contact details 
for an independent advisory service (PALS at each site) 
will also be provided in case external advice is desired by 
participants. Participants will be free to withdraw at any 
time, without any impact on their care.45 46
Interventions
As the control arm of the definitive trial will be ‘current 
normal practice’, the intervention designed for the exper-
imental arm of the definitive trial will be used to evaluate 
the feasibility trial objectives.26–29 As per ‘current normal 
practice’, an APP acting as an FCP will complete the initial 
assessment and physiotherapeutic treatment of partic-
ipants as deemed appropriate through evidence-based 
clinical reasoning and best practice (traditional role). In 
addition to the physiotherapist’s traditional role, the APP 
will have the competence and legal ability to prescribe 
medicines independently. If advice about medication 
or prescription drugs are required/no longer required 
box 1 Participant eligibility criteria
Inclusion Criteria
 ► Male and female patients, aged >18 years.
 ► Non-specific LBP with or without leg pain requiring medication ad-
vice and drug prescription on assessment.
 ► Classified as moderate risk using the STarT Back Tool (classified 
as potentially benefiting from medicines and active physiotherapy 
treatment7).
 ► Able to read/communicate in English (owing to funding restrictions 
for interpreters and translators).
 ► Capable of following the demands inherent of the study.
Exclusion Criteria
 ► Signs of lumbar nerve root compression.82
 ► Red Flags including potential spinal fracture, inflammatory disease, 
infection or malignancy.82
 ► Spinal stenosis.83
 ► Suspicion of or confirmed cauda equina syndrome.84
 ► Does not have capacity to consent.85
 ► Unable to receive email and/or complete online questionnaires.
LBP, low back pain.LBP, low back pain.
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within the multimodal physiotherapeutic context, these 
will be prescribed/de-prescribed by the APP immediately, 
rather than referring the patient back to their GP for 
assessment for medications as per current normal prac-
tice. The medications provided should be taken by the 
patient as prescribed in the time frames discussed in the 
clinical consultation.
outcomes
The literature reports that the use of a core outcome 
set assessing pain intensity, health-related quality of life 
and physical function is required for the assessment of 
non-specific LBP.56 However, no consensus exists with 
regards to the instruments most suitable to measure 
these domains.56 The outcome measures selected for use 
within the trial were informed by a team of subject-ex-
perts including physiotherapists, pharmacists, medical 
practitioners, academics and health-service managers and 
deemed most appropriate to evaluate the study's objec-
tives while attempting to minimise the burden on partic-
ipants. Two primary outcome measures (detailed below) 
were selected as they jointly evaluate the core outcome 
set requirements.56 Details of the secondary outcome 
measures and rationale for selection are found in table 1.
Primary outcome measures
 ► Overall pain, Numerical Rating Scale (NRS): The 
NRS is a unidimensional 11-point scale (0–10) used 
to measure pain intensity, where 0 represents no pain 
and 10 represents maximum pain (eg, the worse pain 
you can possibly imagine).57Patients with pain have 
been shown to prefer the NRS over other pain measure 
including the pain Visual Analogue Scale owing to 
simplicity and clarity.57 58 The NRS has demonstrated 
good reliability, validity and responsiveness and has 
been used extensively in pain research.59–61 A reduc-
tion of 2.5 points on the NRS has been shown to be 
clinically important for chronic LBP.60–62 Participants 
will score pain in three categories: ‘worst pain over 
the last 2 weeks’, ‘least pain over the last 2 weeks’ and 
‘average pain level today’.
 ► RMDQ: The RMDQ is one of the most widely used 
outcome measures for LBP, with well-established 
good levels of validity and reliability.63 The RMDQ has 
Table 1 Secondary outcome measures and their rationale
Outcome Measure Rationale
Health-related quality of 
life (QALY)
EQ-5D 5 L The EQ-5D 5 L is used to measure health-related quality of life demonstrating good reliability and 
validity through psychometric testing.86 If feasibility is found, this measure will inform cost utility in 
a full RCT.
Pain-related fear of 
movement
The TSK The TSK is a 17-item tool that was developed to measure a person’s fear of movement owing 
to LBP. Ongoing fear of movement has been linked to the development of long-term persistent 
pain.87 This outcome measure has been found to show good validity and reliability when 
measuring pain-related fear of movement.88
Physical activity and ActivPal 3 Accelerometer Anecdotal evidence suggests that decreasing sedentary behaviour in people with LBP may have 
significant health benefits,53 reducing risks of obesity, metabolic syndrome, type 2 diabetes 
and mortality.89 Systematic reviews have revealed that physical activity of people with LBP is 
lower or equal to the healthy population90–92; however, there appears to be differing patterns of 
physical behaviour, with the back-pain population engaging in shorter bouts of physical activity 
that are not long enough to incur health benefits (>10 min).92 93 An accelerometer will be used 
to collect data including steps count and sedentary periods.94 To date, no individual brand/
model of accelerometer has been identified as gold standard. The ActivPal 3 has been selected 
for use in this feasibility trial as it has been seen to be more precise and sensitive than other 
accelerometers.94 95
Sleep ActivPal 3 Accelerometer 50%–60% of people experiencing either acute or persistent LBP experience high levels of sleep 
disturbance.96 Poor sleep over long periods of time may lead to depression, obesity, diabetes and 
cardiovascular disease.96 97Patients with LBP suffering with sleep disturbance have been reported 
as twice as likely to be hospitalised.98 Improved sleep has been seen to modulate pain intensity,99 
with poor quality sleep associated with increased pain intensity, fatigue, decreased function and 
psychological stress. An accelerometer will be used to collect sleep duration data alongside 
physical activity and sedentary behaviour.100
Time to return to work 
and nature of return to 
work (eg, full time, part 
time and light duties)
Days Work absence owing to sick leave for work disability is a key issue clinically, socially and 
economically. The minimally clinically important change (MCIC) for time to return to work has 
not been defined due to the specific measurement (days on sick leave) being widely accepted 
and recognition of the measure’s value in social and economic issues rather than an indicator of 
morbidity.62 This measure would therefore be useful when conducting economic evaluation of 
physiotherapist prescribing.
Prescription utilisation, 
participant
Days Time requiring drugs for the treatment of non-specific LBP discussed/prescribed by the advanced 
physiotherapists will be monitored to evaluate the necessity of this measure for future cost-
effectiveness analysis within a full trial.
Number of appointments 
with other healthcare 
professionals about this 
episode of LBP
Number of appointments 
with each type of 
healthcare professional
The number of appointments with other healthcare professionals about the specific episode of 
LBP being studied will be recorded via a question in the outcome questionnaire to evaluate the 
necessity of this measure for future cost-effectiveness analysis within a full trial.
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been selected over its counterparts owing to its supe-
rior measurement properties in patients reporting 
moderate disability demonstrated by those strati-
fied into the medium risk group by the STarT Back 
Tool.7 62 63 The 24-item questionnaire takes approxi-
mately 5 min to complete and includes items assessing 
physical activity, sleep, psychosocial factors, activities 
of daily living, appetite and pain.64 Scores range from 
0 (no disability) to 24 (maximum disability), with a 
change of 3.5 points deemed clinically significant.62
sample size
As the number of FCP physiotherapists that are regis-
tered to prescribe is currently limited,65 three first 
contact APPs (n=3), across three primary care sites 
representative of English geography (x1 capitol city, x1 
regional city, x1 rural town), will recruit, assess and treat 
n=10 participants per APP, to enable the evaluation of 
recruitment rates across clinicians and the feasibility 
of the trial methods in both metropolitan and rural 
healthcare services.27 43 44 This feasibility trial does not 
aim to estimate the sample size required for the full trial 
as feasibility trials for cRCTs have been shown not to 
adequately predict sample size, therefore large numbers 
of participants are not required.43 66 A total sample of 
n=30 patients will be recruited as a sample size of n>20 is 
regarded as adequate when testing feasibility objectives 
for cRCTs.27 28 43 44 This allows for some loss to follow-up 
of participants.
data analysis
A CONSORT diagram will be used to describe the flow of 
participants and lost to follow-up rates. This will be used 
to analyse feasible eligibility, recruitment and follow-up 
rates.30 Only data from fully completed outcome ques-
tionnaires will be included in the data analysis; however, 
the number of partly completed outcome question-
naires will be noted and reasons for this explored in the 
embedded qualitative component of the trial. Data will be 
tabulated, and primary descriptive analysis of the data will 
be completed to test procedure.27 45 46 Causality will not 
be statistically analysed as this is not within the scope of 
this feasibility trial.45 46 The distribution of the scores on 
the RMDQ will be evaluated at baseline, 6 and 12 weeks 
following initial intervention. The percentage of scores 
equalling 0/24 at 12 weeks will be used to measure a 
potential floor effect.67
EMbEddEd quAlItAtIvE CoMPonEnt
design
An embedded qualitative component will be used as 
recommended by current guidance, to address trial 
objectives and to refine and adapt the proposed full trial 
design following evaluation.68 69 The methodology was 
designed and is reported using the Consolidated Criteria 
for Reporting Qualitative Health Research.70
Advanced physiotherapy practitioners
Semistructured in-depth face-to-face interviews with all 
of the APPs (n=3) will be used to evaluate their views 
and experiences about the feasibility, suitability and 
acceptability of the trial, specifically evaluating trials 
objectives.26–29 71 72 Interviews will be undertaken by one 
researcher (TN) following completion of participant 
data collection, to evaluate the research objectives and to 
gather qualitative data regarding the participants’ views, 
perceptions and experiences about taking part, future 
risks and how the trial might be improved.27 28 Question 
design was informed by the methodological literature 
and developed by a team of experts in the fields of physio-
therapy, primary care, NMP, health policy and trial meth-
odology.45 55 A patient and public involvement group 
reviewed the questions for appropriateness and clarity.73 
Prior to completing the interviews, the APP participants 
will be provided with an information sheet and will have 
the opportunity to ask the researcher any questions about 
the interview process. Consent to taking part will be 
gained using a consent form. Interviews will be recorded 
and transcribed verbatim. Transcripts will be returned to 
participants for inspection, comments and corrections 
prior to analysis, to ensure all views and thoughts are 
captured.71
Patients
A focus group of patients will take place following the 
12 weeks assessment point, specifically to evaluate the 
research objectives.27 74 Focus groups are recognised 
to produce data on collective views, generating a rich 
understanding of participants’ experiences.75 A purpo-
sive sample of six to eight patients, representative of ages 
and sexes will be used; this sample size is reported in the 
literature as the optimum.74 The focus group will meet 
in the qualitative laboratory within the CPR Spine at the 
University of Birmingham, UK, ensuring confidentiality. 
The focus group will be conducted by two researchers 
(facilitator and observer) using a predetermined topic 
guide designed to assess the research objectives, devel-
oped by a team of experts in the fields of physiotherapy, 
primary care, NMP, health policy and trial methodology 
and informed by the methodological literature.45 55 The 
topic guide has been reviewed by a patient and public 
involvement group to ensure appropriateness and 
clarity.73 Consent to participate in the focus group will 
be taken prior to the focus group commencing. The 
participants will receive an information leaflet and have 
the opportunity to have any questions answered by the 
researchers. The focus group will be recorded and tran-
scribed verbatim. Transcripts will be returned to partic-
ipants for comments/correction to ensure all views are 
represented.70
Analysis and findings
To fulfil the trial objectives, a thematic analysis approach 
will be used to analyse and synthesise the qualitative 
data.45 76 77 This systematic, inductive and interactive 
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method is recognised to be useful in identifying the key 
thoughts and views of the population being studied. The 
method is useful where there are likely to be both similar-
ities and diversity of opinion and where the intervention 
is novel, often providing explanations alluding to how the 
concerns may be resolved or processed in preparation 
for a full trial.76–79 Focus group and interview transcripts 
will be coded line-by-line using NVivo 11 software (QSR 
International, Melbourne, Australia) by one researcher 
(TN) and be verified by a second researcher (AR).46 77 78 
Rigorous comparative analysis will be completed by one 
researcher (TN) to identify similarities and differences 
within the data, informing the development of descrip-
tive categories which will be linked, merged or split to 
synthesise a conceptual understanding of the data.77 78 To 
avoid single researcher bias, a second researcher (AR) 
will re-interrogate the data to validate or contradict find-
ings.77 Outcomes will then be discussed with a panel of 
experts for confirmation and agreement.76 77 79
Integration: feasibility, suitability and acceptability
Following data analysis of the trial and embedded qualita-
tive components, the quantitative and qualitative data will 
be assessed against a success criterion outlined a priori 
(table 2). The predetermined success criteria were devel-
oped by a team of experts in the fields of physiotherapy, 
primary care, NMP, health policy and trial methodology 
and informed by the methodological literature.45 55 80 
Trial objectives will be considered successful if the success 
criteria are satisfied following the integration of the quan-
titative and qualitative findings.80
Patient and public involvement
Patients with LBP are part of our research team/co-inves-
tigators to ensure that the patient perspective is central. 
There is a PPI representative on both the Trial Manage-
ment Group and Trial Steering Group to ensure that 
patients and the public are involved at all steps in the 
research process.
Patients have contributed to the development of the 
interview/focus group questions, participant information 
sheet, consent form, and importantly to the processes 
of data analysis and interpretation and producing a lay 
summary of findings. They have reviewed this protocol 
and have helped to ensure that their involvement is fully 
considered.
data storage
All data will be electronic and stored in password-pro-
tected computer files that can be accessed only by study 
investigators at the University of Birmingham. Participants 
who choose to disclose personal details will be addition-
ally protected via coding on data files. This coding will be 
kept in a password protected computer file on the Univer-
sity of Birmingham server, only accessible to the research 
team ensuring confidentiality.45 81 These personal data 
and participant contact details (stored during study to 
arrange focus groups and interviews) will be securely 
Table 2 Success criteria
General objectives Success criteria
Eligibility criteria A favourable number of patients fit 
the eligibility criteria to enable the 
stipulated recruitment rate
APPs agreed with the eligibility 
criteria
Recruitment strategy Participants were recruited within the 
time constraints of the local clinical 
environment
Patients and APPs report that they 
were happy with the recruitment 
strategy
Data collection methods Data were collected with ease via 
REDCap and no complications were 
experienced
Data completeness of ≥80%
Patients and APPs report that they 
were happy with the data collection 
methods
Follow-up procedures 100% of participants were contacted 
for follow-up
≥80% completion of follow-up 
outcome measures
Patients and APPs report that 
they were happy with follow-up 
procedures
Specific objectives Success criteria
Feasibility
  Participant recruitment 
rates
Recruitment target of n=10 per 
clinician met in the time available 
(3 months)
  Ease of fitting 
accelerometers
Accelerometers were fitted within 
the allocated clinical time allowed 
with the FCP APP
Patients and APPs report that 
accelerometers were fitted with no 
issues
  Accelerometer data 
collection
REDCap was able to capture the 
data from the accelerometers with 
no errors or data loss
Patients report that they were 
happy with data collection using 
accelerometers/burden within 
subjectively appropriate limits
  Capacity (time and effort) 
of clinicians’ complete trial-
related tasks
APPs report that adequate time 
was allowed to complete all tasks 
required by them during the trail
  Training required by 
clinicians
APPs report that they had adequate 
training to be able to complete the 
tasks required by them during the 
trial
Suitability
  Outcome measures Data completeness of ≥80%
Patients and APPs report that the 
outcome measures were appropriate 
and self-explanatory
  Compliance with wearing 
the accelerometers
Data collected ≥80% of the 
requested time (16 hours/day for 
7 days)
Continued
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destroyed at the end of the study. No participants will be 
identifiable in data presentation or dissemination. The 
confidentiality of data will be preserved when the data 
are transmitted to sponsors and co-investigators by main-
taining the de-personalised data format and ensuring that 
no data are traceable to an individual participant. The 
password-protected files will be retained for 10 years, in 
a confidential, locked storage unit, satisfying university 
code of practice.
EthICs And dIssEMInAtIon
Ethical considerations
The feasibility trial will be conducted in accordance with 
the principles of the Research Governance Framework 
for Health and Social Care. To ensure that the study is 
conducted in an ethical manner within best research 
practice, Health Research Authority (HRA) ethical 
approval was sought via the Integrated Research Applica-
tion System (IRAS) ID 250734.45 81 Approval was granted 
on 30 October 2018. Participants’ inclusion within the 
study will be entirely voluntary, with no incentives offered 
to participants to minimise bias.45 46 Participant consent 
will be gained using an online consent form following 
the provision of information explaining the rationale, 
content and research dissemination plans to ensure 
ethical recruitment of participants.45 81 Participants will 
be free to withdraw at any time.45 46
dissemination of findings
The study’s findings will be disseminated via study reports, 
publication in academic peer-reviewed journals and 
conference presentations.45 46 The results will be commu-
nicated to participants as a summary report written in 
lay language including key findings and plans for future 
research.
dIsCussIon
The results from this prospective, mixed-methods, single-
group feasibility trial with an embedded qualitative 
component will serve to inform researchers about the 
feasibility, suitability and acceptability of the specific 
methods evaluated, in preparation for a full RCT to 
assess the clinical and cost-effectiveness of physiother-
apist prescribing for LBP in primary care. Evidence is 
required by researchers, policy-makers and health-service 
managers to inform decisions regarding the selection of 
appropriate, rigorous, clinically safe and economically 
sound design of a robust, high-quality full RCT with 
low risk of bias. It is anticipated that the results of this 
study will be used in conjunction with ethical evaluation, 
economic and risk analyses, as well as consultation with 
key stakeholders including the British health consumer 
when contemplating change, enhancement or redesign 
of the essential full RCT.
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